Fenofibrate and the kidney: an overview
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Background: Fenofibrate has been used for the management of atherogenic dyslipidaemia for many years. Reports of fenofibrate‐associated increases in serum creatinine (SC r) levels raised concerns regarding deleterious effects on renal function. Design: In this narrative review, we discuss available literature on the effect of fenofibrate on the kidney. Results: Most clinical studies showed a rapid (within weeks) raising effect of fenofibrate on SC r levels. This was often accompanied by declined estimated glomerular filtration rate. Risk predictors of this adverse effect might include increased age, impaired renal function and high‐dose treatment. Also, the concomitant use of medications affecting renal hemodynamics (e.g. angiotensin‐converting enzyme‐inhibitors (ACEi) and angiotensin receptor blockers) may predispose to fenofibrate‐associated increased SC r levels. Interestingly, SC r increases by fenofibrate were transient and reversible even without treatment discontinuation. Furthermore, fenofibrate was associated with a slower progression of renal function impairment and albuminuria in a long‐term basis. Also, fenofibrate might be protective against pathological changes in diabetic nephropathy and hypertensive glomerulosclerosis. In this context, it is uncertain whether fenofibrate‐associated increase in SC r levels mirrors true renal function deterioration. Several theories have been expressed. The most dominant one involved the inhibition of renal vasodilatory prostaglandins reducing renal plasma flow and glomerular pressure. Increased creatinine secretion or reduced creatinine clearance by fenofibrate was also suggested. These hypotheses should be settled by further studies. Conclusions: Fenofibrate may not be a nephrotoxic drug. However, a close monitoring of SC r levels is relevant especially in high‐risk patients. Increases in SC r levels ≥30% can impose treatment discontinuation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371
Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.004 · Cited by 264
New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study
Zhao, Y. Y., Weir, M. A., Manno, M., Cordy, P., Gomes, T., Hackam, D. G., Juurlink, D. N., Mamdani, M., Moist, L., Parikh, C. R., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00401 · Cited by 258
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Park, C. W., Zhang, Y., Zhang, X., Wu, J., Chen, L., Cha, D. R., Su, D., Hwang, M.-T., Fan, X., Davis, L., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5000209 · Cited by 202
Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine
Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186
Keating, G. M., & Croom, K. F. (2007) · Drugs · doi:10.2165/00003495-200767010-00013 · Cited by 169
Fibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Broeders, N., Knoop, C., Antoine, M., Tielemans, C., & Abramowicz, D. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.12.1993 · Cited by 163
Mychaleckyj, J. C., Craven, T., Nayak, U., Buse, J., Crouse, J. R., Elam, M., Kirchner, K., Lorber, D., Marcovina, S., Sivitz, W., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1811 · Cited by 149
Ting, R.-D., Keech, A. C., Drury, P. L., Donoghoe, M. W., Hedley, J., Jenkins, A. J., Davis, T. M. E., Lehto, S., Celermajer, D., Simes, R. J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1109 · Cited by 119
Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People
Ansquer, J.-C., Dalton, R. N., Caussé, E., Crimet, D., Le Malicot, K., & Foucher, C. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.01.014 · Cited by 107
Slinin, Y., Ishani, A., Rector, T., Fitzgerald, P., MacDonald, R., Tacklind, J., Rutks, I., & Wilt, T. J. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.017 · Cited by 99
KLAUSEN, K. P., SCHARLING, H., & JENSEN, J. S. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01679.x · Cited by 83
Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes
Forsblom, C., Hiukka, A., Leinonen, E. S., Sundvall, J., Groop, P.-H., & Taskinen, M.-R. (2010) · Diabetes Care · doi:10.2337/dc09-0621 · Cited by 81
Chen, Y.-J., & Quilley, J. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129197 · Cited by 59
Effect of fenofibrate treatment for hyperlipidaemia on serum creatinine and cystatin C
Ncube, V., Starkey, B., & Wang, T. (2012) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2012.011163 · Cited by 21
Cited by
Inhibition of ferroptosis by up-regulating Nrf2 delayed the progression of diabetic nephropathy
Li, S., Zheng, L., Zhang, J., Liu, X., & Wu, Z. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.10.323 · Cited by 407
Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317
The Evolving Understanding of the Contribution of Lipid Metabolism to Diabetic Kidney Disease
Stadler, K., Goldberg, I. J., & Susztak, K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0611-8 · Cited by 165
Hegade, V. S., Khanna, A., Walker, L. J., Wong, L.-L., Dyson, J. K., & Jones, D. E. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4250-y · Cited by 86
Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030706 · Cited by 79
Metadata
- Authors
- Kostapanos, M. S., Florentin, M., & Elisaf, M. S.
- Venue
- European Journal of Clinical Investigation
- Publisher
- Wiley
- Published
- 2013-03-11
- Volume
- 43
- Issue
- 5
- Pages
- 522-531
- ISSN
- 0014-2972 (ISSN-L)
- 1365-2362
- OpenAlex
- W2092666385
- Cited by
- 65
- References
- 23
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.